Irina Olegovna Bagaeva

Dr. Irina Olegovna Bagaeva

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ESEkaterina Sinitsyna
Ekaterina Sinitsyna
IBIrina Olegovna Bagaeva
Irina Olegovna Bagaeva
EGErik Gandalipov
Erik Gandalipov
EFEvgenia Fedotova
Evgenia Fedotova
Viktor Korzhikov-VlakhViktor Korzhikov-Vlakh
Viktor Korzhikov-Vlakh
Evgenia Korzhikova-VlakhEvgenia Korzhikova-Vlakh
Evgenia Korzhikova-Vlakh
Cancer is still one of the major diseases worldwide. The discovery of new drugs and the improvement of existing ones is one of the areas of priority in the fight against cancer. Dioxadet ([5-[[4,6-bis(aziridin-1-yl)-1,3,5-triazin-2-yl]amino]-2,2-dimethyl-1,3-dioxan-5-yl]methanol) represents one of the promising 1,3,5-triazine derivatives and has cytostatic activity towards ovarian cancer. In this study, we first report the development of dioxadet-bearing nanomedicines based on block-copolymers of poly(ethylene glycol) monomethyl ether (mPEG) and poly(D,L-lactic acid) (PLA)/poly(ε-caprolactone) (PCL) and then conduct an investigation into their characteristics and properties. The preparation of narrow-sized nanoparticles with a hydrodynamic diameter of 100–120 nm was optimized using a nanoprecipitation approach. Thoughtful optimization of the preparation of nanomedicines was carried out through adjustments to the polymer’s molecular weight, the pH of the aqueous medium used for nanoprecipitation, the initial drug amount in respect to the polymer, and polymer concentration in the organic phase. Under optimized conditions, spherical-shaped nanomedicines with a hydrodynamic diameter of up to 230 nm (PDI < 0.2) containing up to 592 ± 22 μg of dioxadet per mg of polymer nanoparticles were prepared. Study of the drug’s release in a model medium revealed the release up to 64% and 46% of the drug after 8 days for mPEG-b-PLA and mPEG-b-PCL, respectively. Deep analysis of the release mechanisms was carried out with the use of a number of mathematical models. The developed nanoparticles were non-toxic towards both normal (CHO-K1) and cancer (A2780 and SK-OV-3) ovarian cells. A cell cycle study revealed lesser toxicity of nanomedicines towards normal cells and increased toxicity towards cancer cells. The IC50 values determined for dioxadet nanoformulations were in the range of 0.47–4.98 μg/mL for cancer cells, which is close to the free drug’s efficacy (2.60–4.14 μg/mL). The highest cytotoxic effect was found for dioxadet loaded to mPEG-b-PCL nanoparticles.

2 October 2026 in Polymers
Verified
Journal Article
Open access
PDF file
IBIrina Olegovna Bagaeva
Irina Olegovna Bagaeva
ESEkaterina Sinitsyna
Ekaterina Sinitsyna
SZS Zmitrichenko
S Zmitrichenko
GTGregorii Tochilnikov
Gregorii Tochilnikov
ETElena Tupikina
Elena Tupikina
Evgenia Korzhikova-VlakhEvgenia Korzhikova-Vlakh
Evgenia Korzhikova-Vlakh
Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD’s circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.

7 September 2026 in European Polymer Journal
Verified
Journal Article
Closed access
IBIrina Olegovna Bagaeva
Irina Olegovna Bagaeva
SSSergey A. Silonov
Sergey A. Silonov
ESEkaterina Sinitsyna
Ekaterina Sinitsyna
YZYuliia Zmitrichenko
Yuliia Zmitrichenko
ANAlexey Nikiforov
Alexey Nikiforov
Evgenia Korzhikova-VlakhEvgenia Korzhikova-Vlakh
Evgenia Korzhikova-Vlakh